A long term prospective observational study of the safety and tolerability of Bramitob® administered twice daily over three 28-day “on”/28-day “off” cycles to patients with cystic fibrosis having severely compromised lung function (Bethkis study) First published 04/02/2016 Last updated 17/12/2018 EU PAS number:EUPAS12292 Study Ongoing